Clinical trial NCT04421820: BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Official title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Colorectal Cancer
Pancreatic Cancer
Gastric Cancers
Cholangiocarcinoma
Lead sponsor: Bold Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2020-06-09
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Randomized - Arm VII only
Primary purpose: TREATMENT

Brief summary: BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.


Eligibility criteria: Inclusion Criteria:

1. Be 18 years or older.
2. Be male or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol (see Table 12. Acceptable Contraceptive Methods.)
3. Histologically and/or cytologically confirmed gastrointestinal tumours that are metastatic or unresectable, and are subject to receive FOLFOX as SOC per investigator's judgement. Participants will have received at least one line of chemotherapy in the metastatic setting. Colorectal cancer: Patients must have received at least 1 prior line of therapy prior to enrollment in this study. Pancreatic cancer: Patients must have received at least 1 prior line of therapy. Gastric cancer: Patients who have not received prior treatment may be included in this study. GEJ (gastroesophageal junction) cancer patients are considered eligible to enter this trial. Cholangiocarcinoma: locally advanced or metastatic biliary tract cancer (intra or extrahepatic cholangiocarcinoma or gallbladder cancer) are eligible to enter this trial. Patients must have received at least 1 prior line of therapy (with gemcitabine-based chemotherapy). Colorectal cancer (ARM VI): Patients must have received at least 2 prior lines of therapy prior to enrollment in this study, one of which was a 5-FU based regimen. Colorectal cancer (ARM VII): Patients must have received only 1 prior line of therapy in the metastatic setting but remain naïve to oxaliplatin prior to enrollment in this study.
4. Have measurable disease according to RECIST v1.1 (at least one measurable lesion).
5. Have an anticipated survival of at least 16 weeks.
6. Be ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.
7. Have adequate organ function, defined as:

   1. Hematologic: ANC ≥ 1.5 x 109/L, Hgb ≥ 9.0 g/dL and platelet count ≥ 100 x 109/L
   2. Hepatic: total bilirubin ≤ 1.5 x ULN (or ≤ 3 x ULN for subjects with Gilbert's Syndrome); transaminases ≤ 2.5 x ULN (may be up to ≤ 5x ULN if clearly due to liver metastases) and ALP ≤ 2.5 x ULN (or ≤ 3 x ULN if liver metastases).
   3. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min.

   c. Urine protein is 0, trace, or +1 on dipstick urinalysis, or \< 1.0 gram on 24-hour urine protein analysis
8. Be on stable doses of any drugs that may affect hepatic drug metabolism or renal drug excretion (e.g., non-steroidal anti-inflammatory drugs, corticosteroids, barbiturates, diphenylhydantoin, narcotic analgesics, probenecid). Such drugs should not be initiated while the subject is participating in this study or have been initiated within 30 days beforehand before the start of treatment. Whenever possible, narcotic analgesic doses should be stable within 30 days prior to study entry and during the first cycle of therapy.
9. Resolved acute effects of any prior therapy before the start of treatment to baseline severity or grade ≤1 CTCAE 5.0 except for adverse events not constituting a safety risk by investigator judgment (such as alopecia)
10. Able to take oral medications (for pre-medications and supportive management)
11. Understand and be able, willing, and likely to fully comply with study procedures and restrictions.
12. Be fully informed about their illness and the investigational nature of the study protocol, and sign a REB-approved Informed Consent Form (ICF).
13. (ARM VII): BRAF wild-type tumour status

Exclusion Criteria:

1. Neuropathy \> grade 2
2. Previous intolerance to or significant reaction secondary to fluorouracil or oxaliplatin
3. Cerebrovascular accident within the past 6 months before the start of treatment.
4. History or presence of central nervous system (CNS) metastasis or leptomeningeal tumours as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam.
5. Any serious medical conditions that might be aggravated by treatment or limit compliance. This includes, but is not limited to uncontrolled psychiatric disorders, serious infections, active peptic ulcer disease and bleeding diathesis
6. Any history of serious cardiac illness including (but not confined to):

   * Previous or active myocardial infarction \< 6 months before the start of treatment
   * Congestive cardiac failure (NYHA III or IV)
   * History of unstable angina pectoris \< 6 months before the start of treatment
   * Recent coronary artery bypass grafting \< 6 months before the start of treatment
   * Uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg)
   * Ventricular arrhythmia \< 6 months before the start of treatment
   * Left ventricular ejection fraction (LVEF) \< 50% as measured either by radionuclide angiography or echocardiogram
   * QTc interval \> 470 msec
7. Hemoptysis, cerebral, or clinically significant gastrointestinal hemorrhage in the past 6 months before the start of treatment
8. Any other known malignancy within 3 years before the start of treatment (with the exception of non-melanoma skin cancer that had undergone curative treatment, cervical cancer in situ, or ductal/lobular carcinoma in situ of the breast that has underwent local treatment
9. Active gastrointestinal tract disease with malabsorption syndrome.
10. Non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease.
11. Treatment with radiation therapy or surgery within 4 weeks prior to starting treatment.
12. Recent history of weight loss \> 10% of current body weight in past 3 months before the start of treatment.
13. Current (within 1 week of the start of the study) or regular use of any medication (including OTC, herbal or homeopathic preparations) that could affect (improve or worsen) the cancer being studied, or could affect the action or disposition of BOLD-100, or its clinical or laboratory assessment, e.g., Coumadin therapy, due to high competitive protein binding.
14. HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
15. Any condition potentially decreasing compliance to study procedures. Concurrent use of another investigational therapy or anti-cancer therapy.
16. Concurrent use of another investigational therapy or anti-cancer therapy within 4 weeks before the start of treatment.
17. Currently breastfeeding
18. Dihydropyrimidine Dehydrogenase (DPD) deficiency
19. Current or prior treatment with potent inhibitors of Dihydropyrimidine Dehydrogenase (DPD)
20. (ARM VII): Prior oxaliplatin treatment in the 1st line setting
21. (ARM VII): Prior exposure to BOLD-100
22. (ARM VII): Subjects with microsatellite-high (MSI-H) Tumours
23. (ARM VII): Concurrent monoclonal antibody therapy for mCRC (anti-EGFR, anti-VEGF or anti-HER2)

Primary outcomes:
measure: Incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Incidence of serious adverse events (SAE) and suspected unexpected serious adverse reactions;
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Incidence of dose-limiting toxicities (DLT)
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Incidence of clinically significant changes or abnormalities from Physical Examinations, ECGs, Vital Signs, Laboratory Results (chemistry, hematology, coagulation, urinalysis), Eastern Cooperative Oncology Group (ECOG) performance status
timeFrame: Screening to Study Discontinuation (an average of 2 months)
Secondary outcomes:
measure: Progression Free Survival (PFS); Overall Response Rate (ORR); Overall Survival (OS)
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Standard PK parameters including Cmin
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Baseline GRP78 biomarker levels (Counts/mL)
timeFrame: Baseline
measure: Changes in GRP78 biomarker levels during treatment (Counts/mL)
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Standard PK parameters including Cmax
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Standard PK parameters including TSS
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Standard PK parameters including CSS
timeFrame: Screening to Study Discontinuation (an average of 2 months)
measure: Standard PK parameters including Vdss
timeFrame: Screening to Study Discontinuation (an average of 2 months)
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: University of California, Los Angeles
state: California
city: Tampa
country: United States
facility: Moffitt Cancer Center
state: Florida
city: Edmonton
country: Canada
facility: Cross Cancer Institue
state: Alberta
city: Hamilton
country: Canada
facility: Juravinski Cancer Centre
state: Ontario
city: Ottawa
country: Canada
facility: The Ottawa Hospital Cancer Centre
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
city: Montreal
country: Canada
facility: Jewish General Hospital
state: Quebec
city: Montréal
country: Canada
facility: McGill University Health Centre Glen Site
state: Quebec
city: Dublin
country: Ireland
facility: St. James Hospital
city: Goyang
country: Korea, Republic of
facility: National Cancer Center
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital - Yonsei University
Study officials:
References: